To Get Help Now
Click Here
 
Today's Date:

J&J Did Not Warn That Levaquin Posed Greater Risk Than Rival Medications

AddThis Social Bookmark Button

In the third Levaquin case to go to trial over Levaquin tendon injuries, and the first to be tried in New Jersey, plaintiff attorney Andy Alonso of Parker Waichman Alonso, LLC., said in close arguments that Executives of J&J’s Ortho-McNeil-Janssen Pharmaceutical unit sought to protect sales by omitting information about Levaquin’s “comparative risk” from its warning label, Business Week reported.

“They should be held to account for not fully disclosing” that they knew Levaquin generated a higher number of reports of Achilles tendon injuries than competing antibiotics, Alonso told a state court jury in Atlantic City, New Jersey, today.

Alonso is representing Paul Gaffney, 67,  and Robert Beare, 72, who were prescribed Levaquin for bronchitis brought on by sinus infection. According to the lawsuit, both men ended up with Achilles tendon injuries that left them unable to walk and required surgery.

In 2008, the FDA required all antibiotics in Levaquin’s class to increase warnings about tendon ruptures, after finding the that class of antibiotics increased the risk of tendon injury by three to four times that of the general population.

J&J faces more than 2,600 US filed lawsuits over the drug.

 

breakinglawsuitnews.com disclaimer: This article: J&J Did Not Warn That Levaquin Posed Greater Risk Than Rival Medications was posted on Thursday, October 13th, 2011 at 7:27 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.